Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 9, 1158
eCollection

Conversion Surgery for Stage IV Gastric Cancer

Affiliations
Review

Conversion Surgery for Stage IV Gastric Cancer

Fei Zhang et al. Front Oncol.

Abstract

The prognosis of stage IV gastric cancer (GC) is poor, with palliative chemotherapy remaining the main therapeutic option. Studies increasingly indicate that patients with unresectable stage IV GC, who undergo gastrectomy with radical intention after responding to several regimens of combined chemotherapy, can achieve good survival outcomes. Thus, surgery aiming at radical resection for unresectable stage IV GC after combined chemotherapy has received increasing attention in recent years. This novel therapeutic strategy was defined as conversion surgery in patients with unresectable stage IV GC and it can associate with significant improved survival when R0 resection can be achieved. Despite the recent advances in conversion surgery for patients with unresectable stage IV GC, selection criteria for combination chemotherapy regimens, indications for conversion surgery, optimal timing to surgery, and postoperative chemotherapy all remain controversial. This article reviews the current state of conversion surgery for unresectable stage IV GC.

Keywords: combined chemotherapy; conversion surgery; conversion therapy; metastatic gastric cancer; stage IV gastric cancer; unresectable gastric cancer.

Figures

Figure 1
Figure 1
Biological categories for conversion surgery introduced by Yoshida et al. (17).

Similar articles

See all similar articles

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. (2018) 68:394–24. 10.3322/caac.21492 - DOI - PubMed
    1. Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, et al. . Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. (2018) 4:1553–68. 10.1200/JCO.2018.36.15_suppl.1568 - DOI - PMC - PubMed
    1. Sano T, Aiko T. New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points. Gastric Cancer. (2011) 14:97–100. 10.1007/s10120-011-0040-6 - DOI - PubMed
    1. Dittmar Y, Rauchfuss F, Goetz M, Jandt K, Scheuerlein H, Heise M, et al. . Non-curative gastric resection for patients with stage 4 gastric cancer–a single center experience and current review of literature. Langenbeck's Arch Surg. (2012) 397:745–53. 10.1007/s00423-012-0902-3 - DOI - PubMed
    1. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. . Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. (2006) 24:4991–7. 10.1200/JCO.2006.06.8429 - DOI - PubMed

LinkOut - more resources

Feedback